Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Prevention of Meningococcal Disease”

45 trials

Showing 20 of 45 results

Large-scale testing (Phase 3)Study completedNCT00657709
What this trial is testing

Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

Who this might be right for
Serogroup B Meningococcal Meningitis
Novartis Vaccines 3,630
Testing effectiveness (Phase 2)Study completedNCT01026974
What this trial is testing

Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine

Who this might be right for
Meningococcal Disease
Novartis Vaccines 120
Testing effectiveness (Phase 2)Study completedNCT01434680
What this trial is testing

Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers

Who this might be right for
Meningococcal DiseaseMeningococcal Meningitis
Novartis 992
Post-approval studies (Phase 4)Study completedNCT00310687
What this trial is testing

Persistence of Immune Response After Vaccination With MCC

Who this might be right for
Prevention of Meningococcal Infection
Novartis 1,244
Large-scale testing (Phase 3)Study completedNCT00310674
What this trial is testing

Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age

Who this might be right for
Prevention of Meningococcal Infection
Novartis 150
Post-approval studies (Phase 4)Study completedNCT02724046
What this trial is testing

Ciprofloxacin for the Prevention of Meningococcal Meningitis

Who this might be right for
Meningitis, Meningococcal
Epicentre 300
Post-approval studies (Phase 4)Study completedNCT00310700
What this trial is testing

Kinetics of B Cell Response in Infants Menjugate Vaccination

Who this might be right for
Prevention of Meningococcal Infection
Novartis 75
Large-scale testing (Phase 3)Study completedNCT00317109
What this trial is testing

Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects

Who this might be right for
Infections, Meningococcal
GlaxoSmithKline 168
Large-scale testing (Phase 3)Study completedNCT00616421
What this trial is testing

Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children

Who this might be right for
Meningococcal Infections
Novartis Vaccines 2,907
Post-approval studies (Phase 4)Study completedNCT00310635
What this trial is testing

Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age

Who this might be right for
Meningococcal Infection
Novartis 241
Large-scale testing (Phase 3)Study completedNCT00291343
What this trial is testing

Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study

Who this might be right for
Infections, Meningococcal
GlaxoSmithKline 296
Testing effectiveness (Phase 2)Study completedNCT00262041
What this trial is testing

Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents

Who this might be right for
Prevention of Meningococcal Disease
Novartis Vaccines 524
Post-approval studies (Phase 4)WithdrawnNCT03431675
What this trial is testing

Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018

Who this might be right for
Meningitis, Meningococcal
Epicentre
Testing effectiveness (Phase 2)Study completedNCT00433914
What this trial is testing

Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants

Who this might be right for
Meningococcal Disease
Novartis Vaccines 60
Large-scale testing (Phase 3)Study completedNCT01423084
What this trial is testing

Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years

Who this might be right for
Meningococcal DiseaseMeningococcal Meningitis
Novartis 344
Large-scale testing (Phase 3)Study completedNCT01911221
What this trial is testing

A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.

Who this might be right for
Prevention of the Meningococcal Disease
Novartis Vaccines 13
Testing effectiveness (Phase 2)Study completedNCT00262002
What this trial is testing

Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants

Who this might be right for
Prevention of Meningococcal Disease
Novartis Vaccines 601
Post-approval studies (Phase 4)Not Yet RecruitingNCT07252804
What this trial is testing

Immunogenicity and Safety of MenB Vaccine in Pediatric Patients With Autoimmune Rheumatic Diseases

Who this might be right for
Autoimmune Rheumatologic Disease
University of Sao Paulo General Hospital 263
Large-scale testing (Phase 3)Study completedNCT00311415
What this trial is testing

Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children

Who this might be right for
Prevention of Meningococcal Infection
Novartis Vaccines 257
Testing effectiveness (Phase 2)Study completedNCT00135486
What this trial is testing

Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT Vaccine and Hib-MenC-TT Vaccine in Infants

Who this might be right for
Infections, Meningococcal
GlaxoSmithKline 500
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation